Patents by Inventor Daniel Gudbjartsson
Daniel Gudbjartsson has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20230417766Abstract: The disclosure provides methods for decreasing mortality risk and/or improving health in a subject. In some aspects, the disclosure provides methods of using one or more biomarkers to determine the risk of mortality, detect an increase or decrease over time in the risk of mortality, or detect an improvement or decline in health of a subject that occurs, for example, over time, in response to therapeutic intervention, or as a result of changes in diet, fitness, or other lifestyle changes. In some other aspects, the disclosure provides methods for treating a subject to reduce the mortality risk of the subject. Additionally, the disclosure provides methods for using changes in the risk of mortality of a subject to monitor the effectiveness of a therapeutic treatment, dietary restrictions, fitness regimen, or other intervention in a subject, and for continuing, discontinuing, or altering the treatment, restrictions, regimen, or intervention accordingly.Type: ApplicationFiled: November 15, 2021Publication date: December 28, 2023Inventors: Kári Stefánsson, Daniel Gudbjartsson, Magnús Úlfarsson, Thjodbjorg Eiriksdottir
-
Publication number: 20170191134Abstract: Certain sequence variants have been found to be useful for correcting Prostate Specific Antigen levels in humans. The invention provides diagnostic applications based on such correction, including methods of diagnosis of prostate cancer.Type: ApplicationFiled: August 8, 2016Publication date: July 6, 2017Applicant: deCODE genetics ehfInventors: Julius Gudmundsson, Daniel Gudbjartsson, Patrick Sulem
-
Publication number: 20160319351Abstract: Polymorphic variants (e.g., certain alleles of polymorphic markers) that have been found to be associated with high blood eosinophil counts, conditions causative of eosinophilia (e.g., asthma, myocardial infarction), and/or hypertension are provided herein. Such polymorphic markers are useful for diagnostic purposes, such as in methods of determining a susceptility, and for prognostic purposes, including methods of predicting prognosis and methods of assessing an individual for probability of a response to a therapeutic agent, as further described herein. Further applications utilize the polymorphic markers of the invention include, screening methods and genotyping methods. The invention furthermore provides related kits, computer-readable medium, and apparatus.Type: ApplicationFiled: June 23, 2015Publication date: November 3, 2016Inventors: Daniel Gudbjartsson, Unnur Steina Bjornsdottir, Patrick Sulem
-
Publication number: 20140227693Abstract: The invention relates to procedure and methods of determining a susceptibility to cardiac arrhythmia, including Atrial Fibrillation, Atrial Flutter and Stroke, by assessing the presence or absence of alleles at polymorphic markers found to be associated with Atrial Fibrillation, Atrial Flutter and Stroke. The invention further relates to kits encompassing reagents for assessing such markers, and diagnostic methods, uses and procedures for utilizing such susceptibility markers.Type: ApplicationFiled: January 13, 2014Publication date: August 14, 2014Applicant: deCODE Genetics ehf.Inventors: Anna Helgadottir, Daniel Gudbjartsson
-
Patent number: 8795963Abstract: The invention relates to procedures and methods of determining a susceptibility to cardiac arrhythmia, including Atrial Fibrillation, Atrial Flutter and Stroke, by assessing the presence or absence of alleles at polymorphic markers found to be associated with risk of these conditions. The invention further relates to kits encompassing reagents for assessing such markers, and diagnostic methods, uses and procedures for utilizing such susceptibility markers.Type: GrantFiled: March 30, 2010Date of Patent: August 5, 2014Assignee: deCODE Genetics ehf.Inventors: Hilma Holm, Daniel Gudbjartsson
-
Patent number: 8796182Abstract: The invention relates to variants that predispose to risk of type 2 diabetes, basal cell carcinoma and breast cancer. It has been discovered that certain genetic variants confer risk of these diseases when inherited from one parent, but not the other. The invention provides methods of disease management, including diagnostic methods, utilizing such parental origin effects.Type: GrantFiled: July 9, 2010Date of Patent: August 5, 2014Assignee: deCODE Genetics ehf.Inventors: Valgerdur Steinthorsdottir, Gudmar Thorleifsson, Daniel Gudbjartsson, Gisli Masson, Augustine Kong
-
Patent number: 8637244Abstract: The invention relates to procedure and methods of determining a susceptibility to cardiac arrhythmia, including Atrial Fibrillation, Atrial Flutter and Stroke, by assessing the presence or absence of alleles at polymorphic markers found to be associated with Atrial Fibrillation, Atrial Flutter and Stroke. The invention further relates to kits encompassing reagents for assessing such markers, and diagnostic methods, uses and procedures for utilizing such susceptibility markers.Type: GrantFiled: December 5, 2007Date of Patent: January 28, 2014Assignee: deCODE Genetics ehf.Inventors: Anna Helgadottir, Daniel Gudbjartsson
-
Publication number: 20130338012Abstract: It has been found that certain alleles of the human MYH6 gene are predictive of risk of certain conditions, including Sick Sinus Syndrome, Atrial Fibrillation, Pacemaker implantation and Thoracic aortic aneurysm, in humans. The invention provides diagnostic applications using such alleles, including methods of determining a susceptibility of Sick Sinus Syndrome and related conditions.Type: ApplicationFiled: November 17, 2011Publication date: December 19, 2013Applicants: ILLUMINA INC., deCODE Genetics ehf.Inventors: Patrick Sulem, Hilma Holm, Daniel Gudbjartsson
-
Publication number: 20130253847Abstract: Polymorphic variants (e.g., certain alleles of polymorphic markers) that have been found to be associated with high blood eosinophil counts, conditions causative of eosinophilia (e.g., asthma, myocardial infarction), and/or hypertension are provided herein. Such polymorphic markers are useful for diagnostic purposes, such as in methods of determining a susceptility, and for prognostic purposes, including methods of predicting prognosis and methods of assessing an individual for probability of a response to a therapeutic agent, as further described herein. Further applications utilize the polymorphic markers of the invention include, screening methods and genotyping methods. The invention furthermore provides related kits, computer-readable medium, and apparatus.Type: ApplicationFiled: December 20, 2012Publication date: September 26, 2013Applicant: deCODE Genetics ehf.Inventors: Daniel Gudbjartsson, Unnur Steina Bjornsdottir, Patrick Sulem
-
Patent number: 8367333Abstract: Polymorphic variants (e.g., certain alleles of polymorphic markers) that have been found to be associated with high blood eosinophil counts, conditions causative of eosinophilia (e.g., asthma, myocardial infarction), and/or hypertension are provided herein. Such polymorphic markers are useful for diagnostic purposes, such as in methods of determining a susceptibility, and for prognostic purposes, including methods of predicting prognosis and methods of assessing an individual for probability of a response to a therapeutic agent, as further described herein. Further applications utilize the polymorphic markers of the invention include, screening methods and genotyping methods. The invention furthermore provides related kits, computer-readable medium, and apparatus.Type: GrantFiled: December 11, 2009Date of Patent: February 5, 2013Assignee: deCODE Genetics ehf.Inventors: Daniel Gudbjartsson, Unnur S. Bjornsdottir, Patrick Sulem
-
Publication number: 20120264636Abstract: The invention relates to procedures and methods of determining a susceptibility to certain vascular conditions, including Atrial Fibrillation, Atrial Flutter and Stroke, by assessing the presence or absence of alleles at polymorphic markers found to be associated with these conditions. The invention further relates to kits encompassing reagents for assessing such markers, and diagnostic methods, uses and procedures for utilizing such markers.Type: ApplicationFiled: October 7, 2010Publication date: October 18, 2012Applicant: deCODE Genetics ehf.Inventors: Hilma Holm, Daniel Gudbjartsson
-
Publication number: 20120220477Abstract: The invention relates to variants that predispose to risk of type 2 diabetes, basal cell carcinoma and breast cancer. It has been discovered that certain genetic variants confer risk of these diseases when inherited from one parent, but not the other. The invention provides methods of disease management, including diagnostic methods, utilizing such parental origin effects.Type: ApplicationFiled: July 9, 2010Publication date: August 30, 2012Applicant: deCODE Genetics ehf.Inventors: Valgerdur Steinthorsdottir, Gudmar Thorleifsson, Daniel Gudbjartsson, Gisli Masson, Augustine Kong
-
Publication number: 20120150032Abstract: Certain sequence variants have been found to be useful for correcting Prostate Specific Antigen levels in humans. The invention provides diagnostic applications based on such correction, including methods of diagnosis of prostate cancer.Type: ApplicationFiled: December 13, 2010Publication date: June 14, 2012Inventors: Julius Gudmundsson, Daniel Gudbjartsson, Patrick Sulem
-
Publication number: 20120021989Abstract: The invention relates to procedures and methods of determining a susceptibility to cardiac arrhythmia, including Atrial Fibrillation, Atrial Flutter and Stroke, by assessing the presence or absence of alleles at polymorphic markers found to be associated with risk of these conditions. The invention further relates to kits encompassing reagents for assessing such markers, and diagnostic 5 methods, uses and procedures for utilizing such susceptibility markers.Type: ApplicationFiled: March 30, 2010Publication date: January 26, 2012Applicant: deCODE Genetics ehf.Inventors: Hilma Holm, Daniel Gudbjartsson
-
Publication number: 20110287946Abstract: The invention discloses genetic variants that have been determined to be susceptibility variants of thyroid cancer. Methods of disease management, including methods of determining susceptibility to thyroid cancer, methods of predicting response to therapy and methods of predicting prognosis of thyroid cancer using such variants are described. The invention further relates to kits useful in the methods of the invention.Type: ApplicationFiled: November 26, 2009Publication date: November 24, 2011Applicant: deCODE genetics ehf.Inventors: Julius Gudmundsson, Patrick Sulem, Daniel Gudbjartsson
-
Publication number: 20110230366Abstract: The invention discloses genetic variants that have been determined to be susceptibility variants of thyroid cancer. Methods of disease management, including determining increased susceptibility to thyroid cancer, methods of predicting response to therapy and methods of predicting prognosis of thyroid cancer using such variants are described. The invention further relates to kits useful in the methods of the invention.Type: ApplicationFiled: August 12, 2009Publication date: September 22, 2011Applicant: deCODE Genetics ehf.Inventors: Julius Gudmundsson, Daniel Gudbjartsson, Patrick Sulem
-
Publication number: 20100160802Abstract: Polymorphic variants (e.g., certain alleles of polymorphic markers) that have been found to be associated with high blood eosinophil counts, conditions causative of eosinophilia (e.g., asthma, myocardial infarction), and/or hypertension are provided herein. Such polymorphic markers are useful for diagnostic purposes, such as in methods of determining a susceptibility, and for prognostic purposes, including methods of predicting prognosis and methods of assessing an individual for probability of a response to a therapeutic agent, as further described herein. Further applications utilize the polymorphic markers of the invention include, screening methods and genotyping methods. The invention furthermore provides related kits, computer-readable medium, and apparatus.Type: ApplicationFiled: December 11, 2009Publication date: June 24, 2010Applicant: deCODE Genetics ehf.Inventors: Daniel Gudbjartsson, Unnur S. Bjornsdottir, Patrick Sulem
-
Publication number: 20090325163Abstract: The invention relates to procedure and methods of determining a susceptibility to cardiac arrhythmia, including Atrial Fibrillation, Atrial Flutter and Stroke, by assessing the presence or absence of alleles at polymorphic markers found to be associated with Atrial Fibrillation, Atrial Flutter and Stroke. The invention further relates to kits encompassing reagents for assessing such markers, and diagnostic methods, uses and procedures for utilizing such susceptibility markers.Type: ApplicationFiled: December 5, 2007Publication date: December 31, 2009Applicant: deCODE Genetics ehfInventors: Anna Helgadottir, Daniel Gudbjartsson